Related Experiment Video
Updated: Aug 28, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Therapeutic Effects of Ceranib-2 and Irinotecan Combination on Colon Cancer
Oğuzhan Selvi1, Canan Vejselova Sezer2, Hüseyin İzgördü3
1Medical Oncology Clinic, Faculty of Medicine, Bezmialem Vakif University, İstanbul 34093, Turkey.
Abstract:
The present study investigated the anticancer effects of irinotecan (IR) combined with the acid ceramidase inhibitor Ceranib-2 in HT-29 human colorectal cancer cells. Cell viability was assessed using the MTT assay, apoptosis was evaluated by Annexin V flow cytometry, and morphological alterations were examined by fluorescence microscopy. Both irinotecan and Ceranib-2 significantly reduced cell viability in a dose-dependent manner. Notably, the combination treatment produced greater growth inhibition than either agent alone (p < 0.01). Morphological analysis revealed pronounced apoptotic features, including nuclear condensation, membrane blebbing, and cytoskeletal disruption, particularly in the combination-treated cells. Annexin V analysis further demonstrated that combined treatment markedly increased apoptotic cell populations compared with single-agent treatments (p < 0.01). These findings suggest that Ceranib-2 enhances the anticancer activity of irinotecan and that this combination may represent a promising therapeutic strategy for colorectal cancer.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

